ADEF
ACTU

ABS Direct Equity Fund’s Actuate Therapeutics ACTU Stock Holding History

ABS Direct Equity Fund’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
50,000
+43,403
+658% +$180K 0.1% 98
2025
Q4 		$40.4K Buy
+6,597
New +$45.3K 0.05% 36

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ABS Direct Equity Fund's ACTU Position: Q1 2026 in Review

ABS Direct Equity Fund increased its Actuate Therapeutics (ACTU) stake by 658% in Q1 2026, buying an estimated $180K and bringing the position to 50,000 shares worth $137K. The position accounts for 0.1% of the portfolio, ranked #98.

ABS Direct Equity Fund first reported a position in ACTU in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • ABS Direct Equity Fund held 50,000 shares of Actuate Therapeutics worth $137K as of Q1 2026.
  • ABS Direct Equity Fund bought 43,403 Actuate Therapeutics shares in Q1 2026, an estimated $180K.
  • Actuate Therapeutics made up 0.1% of ABS Direct Equity Fund's portfolio in Q1 2026, its #98 holding.
  • ABS Direct Equity Fund first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.